Value to direct investor

Post on 15-Jul-2015

29 views 1 download

Transcript of Value to direct investor

Diabetic Nephropathy

Diabetic Retinopathy

Hypercholesterolemia

Oral Mucositis

Gout

Acute Lymphocytic Leukemia

Bone Metastasis

Brain Cancer

Breast Cancer

Cervical Cancer

Chronic Lymphocytic Leukemia

Endometrial Cancer

Ewing Sarcoma

Gastric Cancer

Gastrointestinal Stromal Tumors

Head And Neck Cancer

Hodgkin Lymphoma

Kidney Cancer

Liver Cancer

Malignant Mesothelioma

Medullary Thyroid Cancer

Melanoma

Multiple Myeloma

Non-Hodgkin Lymphoma

Non-Small Cell Lung Cancer

Ovarian Cancer

Pancreatic Cancer

Testicular Cancer

Thyroid Cancer

Age Related Macular Degeneration

Keratoconjunctivitis sicca (Dry Eye)

Retinal Vein Occlusion

Acute Respiratory Distress

Syndrome

Sepsis

Staphylococcal Infections

Acute Coronary Syndrome

Angina Pectoris

Atrial Fibrillation

Coronary Artery Disease (CAD)

Critical Limb Ischemia

Hypertension

Pulmonary Arterial Hypertension

Acute Pain

Anxiety Disorders

Chronic Pain

Dementia

Diabetic Neuropathy

Obsessive-Compulsive Disorder

Osteoarthritis Pain

Parkinson's Disease

Post-Traumatic Stress Disorder

Restless Legs Syndrome

Schizophrenia

Traumatic Brain Injury

Liver Cirrhosis

Childhood Enuresis

Growth Hormone Disorders

Hyperparathyroidism

Hyperthyroidism

Guillain-Barre Syndrome

Cytomegalovirus

Fungal Infections

Gram-Negative Bacterial Infections

H1N1 Infection

Herpes Zoster

HIV-1 Infection

Human Papillomavirus Infections

Staphylococcus Aureus (MRSA)

Cardiovascular Devices

Prosthetic Heart Valve

Peripheral Vascular Devices

Cardiovascular Monitoring & Diagnostic Devices

Cardiovascular Surgery

Cardiac Rhythm Management

Cardiovascular Prosthetic Devices

Interventional Cardiology

Cardiac Assist Devices

Wound Care Management

Hospital Supplies

Syringes and Needles

Disposable Hospital & Surgical Supplies

Drug Delivery Devices

Inhalation Systems

Needle Free Injections

Infusion Systems

Diabetes Care Devices

Insulin Delivery & Glucose Monitoring

Ophthalmic Devices

Cataract Surgery Devices

Ophthalmic Diagnostic Equipment

Refractive Surgery Devices

ENT Devices

Hearing Implants

Diagnostic Devices

Electrosurgical Devices

Dental Equipment & Accessories

Diagnostic Imaging & MRI Systems

C/T Systems & Mammography Equipment

X-Ray & Ultrasound Systems

Nuclear Imaging Equipment

Contrast Media Injectors

Bone Densitometry

Anesthesia and Respiratory Devices

Anesthesia Machines & Disposables

Respiratory Devices & Disposables

Sleep Apnea Diagnostic Systems

Healthcare IT

Medical Imaging Information Systems

Nephrology and Urology Devices

Renal Dialysis Equipment

Orthopedic Devices

Orthobiologics & Arthroscopy

Joint Reconstruction

Trauma Fixation

Orthopedic Prosthetics

Cranium Maxillofacial Fixation (CMF)

Spinal Surgery

Endoscopy Devices & instruments

Rigid & Flexible Endoscope

In Vitro Diagnostics

Genetic Testing

Clinical Chemistry

Hematology

Immuno Chemistry

Infectious Immunology

Histology And Cytology

Patient Monitoring

Multiparameter Patient Monitoring

Micro-Electromechanical Systems

Non-invasive Blood Pressure Monitors

Neurology Devices

Neurostimulation Devices

Interventional Neurology

CSF Management

Neurosurgical Products

Radiosurgery

Value to the

Direct Investor

Healthcare’s Investment Marketplace

Dis

cov

ery

Dev

elo

p -

men

t I

N

D Ph

ase

I

Ph

ase

II

Ph

ase

III N

D

A Ap

pro

va

l

La

un

ch

Gro

wth

Ma

ture

Healthcare Development & Financing Cycle

IPO / Public MarketsVenture CapitalAngels / Founders Private Equity / M&A

SE

ED

EX

IT

… E M E R G I N G G R O W T H C O M PA N I E S

… ‘ L E A D ’ I N V E S T O R S

… D I R E C T I N V E S T O R S

… S T R AT E G I C PA R T N E R S & B U Y E R S

T R A N S F O R M I N G H E A LT H C A R E C A P I TA L M A R K E T S

on behalf of…

Healthcare’s Investment Marketplace

Traditional Alternative Investment Structures

Limited Partners, Family Office,

Endowments, Foreign Trusts, Private Banks,

Sovereign Wealth

Portfolio

Company

#1

Portfolio

Company

#2

Venture

CapitalPrivate

Equity

Growth

EquityHedge

Funds

Lack of ControlNo Flexibility 2% / 20%10-year Fund

Cycles

7-year

“Hold” Periods

Lower Returns /

IRRHigh Fees

Minimal

Transparency

Healthcare’s Investment Bank

HealthiosXchange for Direct Investors

HIGHER RETURNS & IRR

RULES-BASED

INVESTMENT STRATEGY

TOTAL CONTROL

12,000 Investors

Across (10)

Asset Classes

in (37) Countries &

2,000 Strategics in

(46) Market sectors

“Seed-to-Exit”

Direct/Diversified

Investment

NO

Adverse

Selection

Messaging

&

Notifications

Ratings &

Reviews

Rules-Based

Deal Flow

Prediction &

Sentiment Data

Proprietary

Events

(6,000)+

Growth

Companies

NO Fee

NO Carry

Shorter “Exit”

Horizons

Real-Time

Valuations &

Research

Less

Correlation

Reporting &

Communications

Zero

Un-Invested

Capital

Healthcare’s Investment Marketplace

HealthiosXchange: Higher Returns / IRR

Direct investment in the most promising healthcare companies.

Limited Partners, Family Office, Endowments,

Foreign Trusts, Private Banks, Sovereign Wealth

Portfolio

Company

#1

Portfolio

Company

#2

NO FEE… NO CARRY

SHORTENED HOLD

PERIODS

GREATER LIQUIDITY

Venture

Capital

Private

Equity

Growth

Equity

Hedge

Funds

Healthcare’s Investment Marketplace

HealthiosXchange: Rules-Based Investing

Rules-based, direct investing in the most promising healthcare companies.

Limited Partners, Family Office, Endowments,

Foreign Trusts, Private Banks, Sovereign Wealth

Portfolio

Company

#1

Portfolio

Company

#2

1. INSTITUTIONAL

LEADERSHIP

2. STRATEGIC

VALIDATION

3. ESTABLISHED

“EXIT”

PATHWAY

Venture

Capital

Private

Equity

Growth

Equity

Hedge

Funds

Healthcare’s Investment Marketplace

HealthiosXchange: Total Control

Direct investment in the most promising healthcare companies.

Limited Partners, Family Office, Endowments,

Foreign Trusts, Private Banks, Sovereign Wealth

Portfolio

Company

#1

Portfolio

Company

#2

Total Transparency

Direct Access to Management

Influence over Valuation &

Investment Structure

100% Discretion, Flexibility

No Adverse Selection

Ultimate Diversification

Exclusive Deal Diligence

360-Degree Communication

Proprietary Event Calendar

Roadshows, “One-on-One’s”,

Conferences

Venture

Capital

Private

Equity

Growth

Equity

Hedge

Funds

Healthcare’s Investment Bank

HealthiosXchange for Direct Investors

HIGHER RETURNS & IRR

RULES-BASED

INVESTMENT STRATEGY

TOTAL CONTROL

12,000 Investors

Across (10)

Asset Classes

in (37) Countries &

2,000 Strategics in

(46) Market sectors

“Seed-to-Exit”

Direct/Diversified

Investment

NO

Adverse

Selection

Messaging

&

Notifications

Ratings &

Reviews

Rules-Based

Deal Flow

Prediction &

Sentiment Data

Proprietary

Events

(6,000)+

Growth

Companies

NO Fee

NO Carry

Shorter “Exit”

Horizons

Real-Time

Valuations &

Research

Less

Correlation

Reporting &

Communications

Zero

Un-Invested

Capital